Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
22 mai 2024 08h30 HE
|
Optimi Health Corp.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
Blue Mountain Appoints Chief Growth Officer to Spearhead Global Expansion and Strategic Partnerships in Life Sciences Sector
21 mai 2024 09h00 HE
|
Blue Mountain
Blue Mountain names Keith Pensabene as Chief Growth Officer, leading global growth and strategic partnerships in the life sciences sector.
Optimi Health Provides Corporate Update
10 mai 2024 08h50 HE
|
Optimi Health Corp.
Optimi Health provides corporate update.
Blue Mountain Appoints Global Head of Marketing to Bolster Growth and Secure its Position as the EAM Industry Standard in the Life Sciences Sector
24 avr. 2024 09h00 HE
|
Blue Mountain
STATE COLLEGE, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- Blue Mountain, the leader in GMP-compliant EAM (Enterprise Asset Management) software for life sciences, is pleased to announce the appointment...
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
23 avr. 2024 08h18 HE
|
Optimi Health Corp.
Optimi Health announces innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre.
Blue Mountain Achieves SOC 2 Compliance, Demonstrating Commitment to Data Security and Trustworthiness
10 avr. 2024 09h00 HE
|
Blue Mountain
STATE COLLEGE, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Blue Mountain, the leader in GMP-compliant EAM (Enterprise Asset Management) software for life sciences, proudly announces its achievement of...
Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute
09 avr. 2024 09h13 HE
|
Optimi Health Corp.
Optimi signs international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
05 avr. 2024 08h58 HE
|
PharmAla Biotech
PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract
02 avr. 2024 07h30 HE
|
Optimi Health Corp.
Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.
PharmAla Biotech Signs Sale Agreement with Numinus
26 mars 2024 08h55 HE
|
PharmAla Biotech
PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference